JP2021523129A5 - - Google Patents
Info
- Publication number
- JP2021523129A5 JP2021523129A5 JP2020562156A JP2020562156A JP2021523129A5 JP 2021523129 A5 JP2021523129 A5 JP 2021523129A5 JP 2020562156 A JP2020562156 A JP 2020562156A JP 2020562156 A JP2020562156 A JP 2020562156A JP 2021523129 A5 JP2021523129 A5 JP 2021523129A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- combination
- hcv
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669007P | 2018-05-09 | 2018-05-09 | |
| US62/669,007 | 2018-05-09 | ||
| PCT/US2019/031459 WO2019217643A1 (en) | 2018-05-09 | 2019-05-09 | Combination therapy for treatment of hcv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523129A JP2021523129A (ja) | 2021-09-02 |
| JP2021523129A5 true JP2021523129A5 (enExample) | 2022-05-17 |
| JP7381493B2 JP7381493B2 (ja) | 2023-11-15 |
Family
ID=66641500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562156A Active JP7381493B2 (ja) | 2018-05-09 | 2019-05-09 | Ｈｃｖを治療するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11752166B2 (enExample) |
| EP (1) | EP3790542B1 (enExample) |
| JP (1) | JP7381493B2 (enExample) |
| KR (1) | KR20210018806A (enExample) |
| CN (1) | CN112203652A (enExample) |
| AU (1) | AU2019265740A1 (enExample) |
| CA (1) | CA3096916A1 (enExample) |
| MX (1) | MX2020011912A (enExample) |
| TW (1) | TWI833753B (enExample) |
| WO (1) | WO2019217643A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022015982A1 (en) * | 2020-07-17 | 2022-01-20 | The Regents Of The University Of California | Compositions and methods for treating viral infections |
| AU2022291927A1 (en) | 2021-06-17 | 2024-01-04 | Atea Pharmaceuticals, Inc. | Advantageous anti-hcv combination therapy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1395571A1 (en) | 2001-06-11 | 2004-03-10 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| EP2363396A1 (en) | 2001-06-11 | 2011-09-07 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
| US6936629B2 (en) | 2001-12-21 | 2005-08-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| ATE466856T1 (de) | 2002-12-10 | 2010-05-15 | Virochem Pharma Inc | Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen |
| AU2003291886A1 (en) | 2002-12-10 | 2004-06-30 | Virochem Pharma Inc. | Thiophenederivatives for the treatment of flavivirus infections |
| DE60332482D1 (de) | 2002-12-10 | 2010-06-17 | Virochem Pharma Inc | Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen |
| DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| JP5030947B2 (ja) | 2005-05-13 | 2012-09-19 | ヴァイロケム・ファーマ・インコーポレーテッド | フラビウイルス感染の治療及び予防のための化合物及び方法 |
| WO2008017688A1 (en) | 2006-08-11 | 2008-02-14 | Smithkline Beecham Corporation | 2-carboxy thiophene derivatives as anti-viral agents |
| WO2008043791A2 (en) | 2006-10-13 | 2008-04-17 | Smithkline Beecham Corporation | Thiophene derivatives for treating hepatitis c |
| SG176488A1 (en) | 2006-11-15 | 2011-12-29 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
| ATE524465T1 (de) | 2006-11-17 | 2011-09-15 | Glaxosmithkline Llc | 2-carboxy-thiophen-derivate als viruzide |
| GB0707092D0 (en) | 2007-04-12 | 2007-05-23 | Smithkline Beecham Corp | Compounds |
| GB0712393D0 (en) | 2007-06-26 | 2007-08-01 | Smithkline Beecham Corp | Compounds |
| US9809616B2 (en) | 2012-10-29 | 2017-11-07 | Emory University | Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer |
| CN106661004A (zh) * | 2014-04-15 | 2017-05-10 | 共晶制药股份有限公司 | 丙型肝炎病毒的有效和选择性抑制剂 |
| TWI731854B (zh) * | 2015-03-23 | 2021-07-01 | 美商共結晶製藥公司 | Ｃ型肝炎病毒聚合酶之抑制劑 |
| US9937160B2 (en) * | 2015-07-16 | 2018-04-10 | Cipla (UK) Limited | Thienopyridine derivative for the treatment of hepatitis C infections |
-
2019
- 2019-05-09 CN CN201980030086.3A patent/CN112203652A/zh active Pending
- 2019-05-09 AU AU2019265740A patent/AU2019265740A1/en not_active Abandoned
- 2019-05-09 US US17/047,209 patent/US11752166B2/en active Active
- 2019-05-09 MX MX2020011912A patent/MX2020011912A/es unknown
- 2019-05-09 CA CA3096916A patent/CA3096916A1/en active Pending
- 2019-05-09 KR KR1020207033655A patent/KR20210018806A/ko not_active Ceased
- 2019-05-09 TW TW108116038A patent/TWI833753B/zh active
- 2019-05-09 JP JP2020562156A patent/JP7381493B2/ja active Active
- 2019-05-09 WO PCT/US2019/031459 patent/WO2019217643A1/en not_active Ceased
- 2019-05-09 EP EP19726259.5A patent/EP3790542B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521118A5 (enExample) | ||
| JP2004509061A5 (enExample) | ||
| JP2008518943A5 (enExample) | ||
| RU2011127080A (ru) | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич | |
| JP2009535352A5 (enExample) | ||
| JP2014530874A5 (enExample) | ||
| JP2013529627A5 (enExample) | ||
| JP2011519364A5 (enExample) | ||
| RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| RU2329050C2 (ru) | Комбинация ингибиторов цитохром-р450-зависимых протеаз | |
| WO1995003056A1 (en) | Hepatitis c virus proliferation inhibitor | |
| JP2010503396A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| JP2017514911A5 (enExample) | ||
| RU2012136824A (ru) | Способы лечения вирусной инфекции гепатита с | |
| Sun et al. | Recent progress in potential anti-hepatitis B virus agents: structural and pharmacological perspectives | |
| JP2002528502A5 (enExample) | ||
| JP2018532797A5 (enExample) | ||
| CN102083435A (zh) | 特拉匹韦给药方案 | |
| NZ598465A (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| JP2021522802A5 (enExample) | ||
| JP2024525164A5 (enExample) | ||
| JP2023518390A (ja) | ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物 | |
| CN104780921A (zh) | Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合 | |
| RU2013129824A (ru) | Новое лечение инфекции вируса гепатита с |